Beigene Ltd
ONC
View Detailed Chart
316.050USD
+9.030+2.94%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
32.16BMarket Cap
513.88P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+2.94%
5 Days
-0.94%
1 Month
-10.67%
6 Months
+25.03%
Year to Date
+71.11%
1 Year
+80.89%
View Detailed Chart
TradingKey Stock Score of Beigene Ltd
Currency: USD Updated: 2025-12-19Key Insights
Beigene Ltd's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 40/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 390.24.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Beigene Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
24
analysts
Buy
Current Rating
390.243
Target Price
+19.53%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Beigene Ltd Highlights
StrengthsRisks
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 169.10% year-on-year.
Overvalued
The company’s latest PE is 513.88, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 40.04M shares, decreasing 5.01% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 307.00 shares of this stock.
Beigene Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Beigene Ltd Info
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
Ticker SymbolONC
CompanyBeigene Ltd
CEOOyler (John Victor)
Websitehttps://beonemedicines.com/
FAQs
What is the current price of Beigene Ltd (ONC)?
The current price of Beigene Ltd (ONC) is 316.050.
What is the symbol of Beigene Ltd?
The ticker symbol of Beigene Ltd is ONC.
What is the 52-week high of Beigene Ltd?
The 52-week high of Beigene Ltd is 385.220.
What is the 52-week low of Beigene Ltd?
The 52-week low of Beigene Ltd is 170.990.
What is the market capitalization of Beigene Ltd?
The market capitalization of Beigene Ltd is 32.16B.
What is the net income of Beigene Ltd?
The net income of Beigene Ltd is -644.79M.
Is Beigene Ltd (ONC) currently rated as Buy, Hold, or Sell?
According to analysts, Beigene Ltd (ONC) has an overall rating of Buy, with a price target of 390.243.
What is the Earnings Per Share (EPS TTM) of Beigene Ltd (ONC)?
The Earnings Per Share (EPS TTM) of Beigene Ltd (ONC) is 0.615.
Related Instruments
+1.32%
-0.88%
+1.75%
+0.83%
+0.60%
+0.38%
+0.91%
+1.03%
+2.32%
+0.60%
+0.40%
+1.97%
+1.63%
+1.21%
+0.65%
+0.66%
+2.57%
0.00%
-0.44%
+1.06%
